HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with the final size and terms subject to market conditions. The company intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities, and support working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is acting as sole bookrunner.
This capital raise comes on the heels of significant regulatory milestones for HeartBeam. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam’s platform is designed to be the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling portable cardiac monitoring outside traditional medical facilities. With over 20 issued patents, the company aims to redefine cardiac health management by providing actionable heart intelligence to physicians and patients.
The offering underscores HeartBeam’s commitment to scaling its technology and capturing market share in the rapidly evolving cardiac care sector. By focusing on AI enhancements and extended-wear patch development, the company is positioning itself at the intersection of remote patient monitoring and artificial intelligence, a growing area of interest for investors and healthcare providers alike. The proceeds will also support working capital needs, ensuring the company can sustain its operational momentum.
For investors, the offering represents both an opportunity and a risk, as it dilutes existing shareholders but provides necessary capital for growth. The success of HeartBeam’s commercial strategy will depend on its ability to secure partnerships, reimbursement codes, and clinical adoption. The company’s technology has the potential to reduce hospital visits and enable earlier detection of cardiac events, which could lower healthcare costs and improve patient outcomes.
More details on the offering are available in the full press release at https://ibn.fm/pxFOz. Additionally, the company’s cleared indications for use can be found at https://www.heartbeam.com/indications. For ongoing updates, investors can visit the company’s newsroom at https://ibn.fm/BEAT.
